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1 These authors contributed equally to this work.Mitochondrial peroxiredoxin 3 (Prx 3) is rapidly oxidized in cells exposed to phenethyl isothiocya-
nate (PEITC) and auranoﬁn (AFN), but the mechanism of oxidation is unclear. Using HL-60 cells
deplete of mitochondrial DNA we show that peroxiredoxin 3 oxidation and cytotoxicity requires a
functional respiratory chain. Thioredoxin reductase (TrxR) could be inhibited by up to 90% by auran-
oﬁn without direct oxidation of peroxiredoxin 3. However, inhibition of thioredoxin reductase pro-
moted peroxiredoxin 3 oxidation and cytotoxicity in combination with phenethyl isothiocyanate or
antimycin A. We conclude that rapid peroxiredoxin 3 oxidation occurs as a consequence of
increased oxidant production from the mitochondrial respiratory chain.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Peroxiredoxin 3 (Prx 3) is an abundant mitochondrial protein
that reacts rapidly with hydrogen peroxide, and is likely to be a
key regulator of mitochondrial hydrogen peroxide levels [1]. Prx
3 is oxidized by hydrogen peroxide to a disulﬁde-linked dimer,
and is dependent on the thioredoxin system for recycling to the re-
duced form. Accumulation of oxidized Prx 3 has been detected dur-
ing ischemia [2] and apoptosis [3–5] and in all of these models the
redox status of the cytoplasmic Prxs are unaltered, indicating a
speciﬁc mitochondrial event.
Prx 3 has been proposed to play a role in the regulation of apop-
tosis, with alterations in expression modulating cellular sensitivity
to pro-apoptotic stimuli [6,7]. While various redox events are pro-
posed to be involved in apoptosis signaling, it is difﬁcult to deter-
mine whether they are a cause or consequence of apoptosis
induction. Two inducers, phenethyl isothiocyanate (PEITC) and
auranoﬁn (AFN), trigger substantial oxidation of Prx 3 within
30 min and prior to other major apoptotic events [4,5], indicatingchemical Societies. Published by E
aleimide; PEITC, phenethyl
l DNA deplete; TrxR, thiore-
Hampton).an early disruption of mitochondrial redox homeostasis. However,
the mechanism underlying the oxidation of Prx 3 and its signiﬁ-
cance is unclear.
Prx 3 oxidation could result from increased mitochondrial
hydrogen peroxide production or impairment of the thioredoxin
(Trx)/thioredoxin reductase (TrxR)/NADPH system responsible for
reducing Prxs. The major source of mitochondrial hydrogen perox-
ide is dismutation of superoxide generated by respiratory com-
plexes [8]. In this study we compared the response of wild-type
HL-60 leukemia cells with those lacking mitochondrial DNA to
determine the importance of a functional respiratory chain for
Prx 3 oxidation. AFN, an inhibitor of TrxR [9], was also used to
determine the relative importance of thioredoxin system in main-
taining Prx 3 in its reduced form.2. Materials and methods
2.1. Materials
Cell culture materials were from Invitrogen New Zealand Ltd.
(Auckland, New Zealand). PEITC was from Sigma Chemical Co.
(St. Louis, MO, USA). Auranoﬁn was from ICN Biomedicals Inc.
(Costa Mesa, CA, USA). Complete™ protease inhibitors and CHAPS
were from Roche Diagnostics (Manheim, Germany). Rabbit poly-
clonal antibodies to Prx 3 and Trx 1 were from Abfrontier Co.lsevier B.V. All rights reserved.
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R&D Systems (Minneapolis, MN, USA). Horseradish peroxidase-
conjugated goat anti-rabbit IgG and rabbit anti-goat IgG were from
Sigma Chemical Co. Hybond-PVDF membrane and enhanced
chemiluminescence (ECL™) western blotting system were from
GE Healthcare (Buckinghamshire, England). All other chemicals
and reagents were from Sigma Chemical Co. and BDH Laboratory
Supplies (Poole, England).
2.2. Cell culture
The mitochondrial DNA deplete (q0) and WT HL-60 cells used in
this study were generously provided by Prof. Mike Berridge of the
Malaghan Institute of Medical Research (Wellington, New Zea-
land). The q0 cells had been generated by culturing HL-60 cells in
the presence of ethidium bromide for 6–8 weeks and the lack of
mtDNA conﬁrmed by PCR [10]. Cells were grown in DMEM supple-
mented with 10% fetal bovine serum (FBS), 2 mM glutamate, 1 mM
pyruvate and 50 lg/ml uridine, and maintained at 37 C in a
humidiﬁed atmosphere with 5% CO2. Cells were harvested in the
exponential phase of growth (between 0.4 and 0.8  106 cells/
ml). WT and q0 HL-60 cells were cultured and treated in full DMEM
media containing pyruvate and uridine. Removal of pyruvate and
uridine halted growth of the q0 cells but had no effect on WT cell
growth (not shown).
2.3. Immunoblot detection of the Prxs
Treated cells were pelleted and resuspended in N-ethylmalei-
mide (NEM) buffer (40 mM HEPES, pH 7.4, containing 50 mM NaCl,
1 mM EDTA, 1 mM EGTA, protease inhibitors, and 100 mM NEM).
After 15 min incubation cells were lysed by addition of 1% CHAPS
and clariﬁed by centrifugation. Lysates containing 10 lg protein
were combined in a 2:1 ratio with non-reducing sample loading
buffer (62.5 mM Tris–HCl pH 6.8, 10% glycerol, 2% SDS, 0.025% bro-
mophenol blue) and resolved by SDS–PAGE. Proteins were trans-
ferred to PVDF membrane, probed with primary and secondary
antibody and visualized by using a peroxidase system with en-
hanced chemiluminescence (ECL™). Images were obtained using
a ChemiDoc™ XRS system (Bio-Rad, Hercules, CA) and densitome-
try of scanned images was undertaken using Quantity One soft-
ware (Bio-Rad, Hercules, CA).
2.4. Flow cytometric analysis of cell viability
Treated cells (2  105) were resuspended in PBS containing
5 lg/ml PI. Cells were incubated in the dark for 10 min before anal-
ysis of the percentage PI-positive cells using a Cytomics FC500 MPL
ﬂow cytometer (Beckman Coulter, Fullerton, CA).
2.5. Immunoblot detection of the redox state of the Trxs
Treated cells (2  106) were pelleted and resuspended in 80 ll
NEM buffer containing 1% CHAPS. After 30 min incubation lysates
were clariﬁed by centrifugation and desalted using a micro spin
column (Bio-Rad, Hercules, CA, USA) pre-equilibrated with extract
buffer (40 mM HEPES, pH 7.4, containing 50 mM NaCl, 1 mM EDTA,
1 mM EGTA). The eluant was incubated with 5 mM dithiothreitol
for 30 min before alkylation with 25 mM a-methoxy-x-ethyl-
maleimide poly(ethylene glycol) 2 kDa (MalPEG-2kDa, Iris Biotech
GmbH, Marktredwitz, Germany) for 30 min. Alkylated protein was
extracted by acetone precipitation, resuspended in reducing
sample buffer (sample loading buffer containing 700 mM b-
mercaptoethanol), resolved by SDS–PAGE and detected by immu-
noblotting as described above.2.6. Preparation of mitochondrial and cytosolic fractions
Following treatment, 3  107 HL-60 cells were collected and
resuspended in 1 ml mitochondrial isolation buffer (20 mM
HEPES–KOH, pH 7.5, containing 10 mM KCl, 1.5 mM MgCl2, 1 mM
EDTA, 1 mM EGTA, 0.25 M sucrose and protease inhibitors). Selec-
tive permeabilization of the plasma membrane was achieved by
addition of 100 lg digitonin. Samples were brieﬂy vortexed before
centrifugation at 650g for 10 min. The supernatant was removed
and centrifuged at 12 500g for 10 min. The resulting supernatant
(cytosolic fraction) was removed while the pellet (mitochondrial
fraction) was resuspended in 50 ll of mitochondrial isolation buf-
fer containing 2% CHAPS. Mitochondrial fractions were clariﬁed by
centrifugation at 15 000g for 4 min. The purity of the cytosolic
andmitochondrial preparations was conﬁrmed by immunoblotting
against Prx 2 (cytosolic) and Prx 3 (mitochondrial) under reducing
conditions.
2.7. TrxR assay
The activity of TrxR was measured using a modiﬁed DTNB
reduction assay [11]. Treated cells were pelleted and resuspended
in extract buffer (40 mM HEPES, pH 7.4, containing 50 mM NaCl,
1 mM EDTA, 1 mM EGTA) containing 1% CHAPS and protease inhib-
itors. Cell lysates (or subcellular fractions) were transferred to a
microplate and mixed with 200 ll of 5 mM DTNB in PE buffer
(100 mM potassium phosphate, pH 7.0, 10 mM EDTA) and the reac-
tion was initiated by addition of 200 lM NADPH. The relative
activity of TrxR was determined as the difference between DA412
nm before and after the addition of NADPH.
2.8. Statistics
Statistical analyses were performed with the software package
SigmaStat (Systat, San Rafael, CA, USA).3. Results
Conversion of Prx 3 reduced monomer to oxidized dimer was
observed following treatment of wild-type (WT) HL-60 cells with
PEITC and the TrxR inhibitor AFN (Fig. 1A and B). To determine
the role of mitochondrial respiratory complexes in the oxidation
of Prx 3, we also assessed the response of q0 HL-60 cells. No in-
crease in oxidation was observed following treatment of q0 HL-
60 cells with PEITC (Fig. 1A) or AFN (Fig. 1B). Assessment of cell
viability 24 h after treatment revealed that the q0 cells were also
considerably more resistant than WT HL-60 cells to both com-
pounds (Fig. 1C and D). This indicates that a fully functional respi-
ratory chain is critical for both Prx 3 oxidation and subsequent
cytotoxicity.
Given that the redox state of Prx 3 is regulated by Trx 2, we
examined the redox status of Trx 1 (cytosolic) and Trx 2 (mito-
chondrial) following treatment with PEITC or AFN. The redox state
of Trx was investigated by labeling reversibly oxidized thiols with
MalPEG-2kDa and visualizing migration shifts by immunoblotting.
Consistent with the Prx 3 results, Trx 2 was almost completely con-
verted to an oxidized form in WT HL-60 cells following treatment
with PEITC (Fig. 2A) or AFN (Fig. 2B), yet there was only a subtle
increase in Trx 2 oxidation in the q0 HL-60 cells. In contrast, only
minor Trx 1 oxidation was observed and this was similar in both
WT and q0 HL-60 cells.
The ability of PEITC and AFN to inhibit TrxR was assessed in
both WT and q0 HL-60 cells. PEITC inhibited TrxR in a dose-depen-
dent manner with an IC50 of 20 lM, while AFN was considerably
more potent with an IC50 of 0.25 lM (Fig. 3A). There was no
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Fig. 1. PEITC and AFN induced Prx3 oxidation and cytotoxicity requires a functional respiratory chain. (A) and (B) WT (d) and q0 HL-60 (s) cells were exposed to 0–40 lM
PEITC (A) or 0–4 lM AFN (B) for 60 or 30 min, respectively, before cells were harvested. Prx 3 oxidation was monitored by western blotting of non-reducing SDS–PAGE gels.
Densitometry of scanned images using Quantity One software (Bio-Rad) was undertaken to quantify Prx 3 oxidation.  Indicates a signiﬁcant difference (p < 0.001) between
treated and untreated cells as determined by a one-way repeated measures ANOVA with Holm-Sidak multiple comparison (Systat). (C) and (D) Cell viability was measured
after 24 h exposure under the same conditions as described above. Values are the mean and S.E. of four independent experiments. # Indicates a signiﬁcant difference
(p < 0.001) between cell types at each dose as determined by a two-way repeated measures ANOVA with Bonferroni multiple comparison (Systat).
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inspection of the AFN dose response data reveals that AFN almost
completely inhibited TrxR activity at doses that had little effect on
the redox state of Prx3. For example, 0.5 lM AFN inhibited TrxR by
approximately 90%, but signiﬁcant Prx 3 oxidation was not de-
tected until cells were exposed to 2 lM AFN (Figs. 3A and 1B).Since PEITC had a limited effect on TrxR activity at concentrations
that oxidized Prx 3 (Figs. 3A and 1A), we conclude that it is oper-
ating independent of its effect on TrxR.
To conﬁrm that both compounds were able to effectively inhibit
both TrxR1 (cytosolic) and TrxR2 (mitochondrial), HL-60 cells were
fractionated into cytosolic and mitochondrial preparations prior to
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Fig. 2. PEITC and AFN induced oxidation of Trx 2 requires a functional respiratory chain. WT and q0 HL-60 cells were exposed to 0–40 lM PEITC (A) or 0–4 lM AFN (B) for 60
or 30 min, respectively, before being harvested and resuspended in buffer containing NEM. Reversibly oxidized thiols were PEGylated and samples were immunoblotted for
Trx 1 and Trx 2. Blots are representative of three independent experiments.
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Fig. 3. PEITC and AFN inhibit TrxR. Cells were exposed to PEITC or AFN for 60 or 30 min, respectively, before being harvested for extraction. (A) PEITC and AFN inhibit TrxR
activity in both WT (d) and q0 (s) HL-60 cells. Cell lysates were assessed for TrxR activity by measuring the NADPH-dependent reduction of DTNB. The speciﬁc TrxR activity
in untreated WT and q0 HL-60 cells was similar (WT = 273 ± 26 DmAU412nm/min/mg; q0 = 263 ± 34 DmAU412nm/min/mg). (B) PEITC and AFN inhibit both cytosolic (d) and
mitochondrial (s) TrxR activity. Cells were fractionated into cytosolic and mitochondrial extracts and TrxR activity in each fraction was measured. Inset: Purity of the
cytosolic (C) and mitochondrial (M) extracts was conﬁrmed by immunoblotting against Prx 2 (cytosolic) and Prx 3 (mitochondrial). Values are the mean and S.E. of three
independent experiments.
1260 K.K. Brown et al. / FEBS Letters 584 (2010) 1257–1262the determination of TrxR activity. Consistent with our previous
studies [4,5], PEITC and AFN inhibited both isoforms of TrxR, with
cytosolic TrxR1 exhibiting a slightly greater extent of inhibitionthan mitochondrial TrxR2 (Fig. 3B). Consequently, the oxidation
of Prx 3 observed with PEITC and AFN does not seem to be associ-
ated with differential inhibition of mitochondrial TrxR.
K.K. Brown et al. / FEBS Letters 584 (2010) 1257–1262 1261Low doses of AFN were used to determine if TrxR inhibition
could sensitize Prx 3 to oxidation. The complex III inhibitor anti-
mycin A increases mitochondrial oxidant production [12], and it
triggered Prx 3 oxidation in HL-60 cells (Fig. 4A). Antimycin A
did not affect cellular TrxR activity, and it did not cause Prx 3 oxi-
dation in the q0 HL-60 cells (data not shown). AFN at 0.5 lM pro-
moted the oxidation of Prx 3 in the presence of antimycin A
(Fig. 4A), with a synergistic increase in cytotoxicity (Fig. 4C). AFN
was also able to sensitize cells to PEITC-triggered Prx 3 oxidation
and cytotoxicity (Fig. 4B and D).4. Discussion
Oxidation of mitochondrial Prx 3 has been observed following
treatment of cells with isothiocyanates and AFN [4,5], but the
mechanism of oxidation has not been elucidated. Two possibilities
exist for promoting the accumulation of oxidized Prx 3: an increase
in mitochondrial oxidant production, or direct inhibition of theControl AFN Anti A AFN+
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Fig. 4. TrxR inhibition sensitizes Prx 3 to oxidation by antimycin A and PEITC and enhan
10 lM antimycin A for 30 min (A) or 5 lM PEITC for 60 min (B) in the presence or absen
the same conditions as described above. Values are the mean and S.E. of at least three
indicated treatments as determined by a one-way repeated ANOVA with Holm-Sidak mTrx/TrxR/NADPH system necessary for recycling the oxidized pro-
tein. We have determined that the redox state of Prx 3 is resilient
to inhibition of TrxR over the short periods examined in this study.
While the TrxR inhibitor AFN caused Prx 3 oxidation at high doses,
it was unable to trigger rapid accumulation of oxidized Prx 3 at
doses where substantial inhibition of TrxR activity occurred. In-
stead, increased oxidation was dependent on a functional mito-
chondrial respiratory chain, indicating a central role for hydrogen
peroxide generated by dismutation of superoxide derived from
respiratory complexes. We therefore propose that PEITC increases
the rate of oxidant generation from the respiratory chain. It is also
possible that higher concentrations of AFN increase the endoge-
nous ﬂux of respiratory chain oxidants, but that is more difﬁcult
to separate from its effects on TrxR activity at lower doses. Regard-
less, the mitochondrial respiratory chain is vital for driving Prx 3
oxidation and the subsequent cytotoxicity associated with both
compounds.
Mitochondria have been reported to be involved in isothiocya-
nate- and AFN-mediated cytotoxicity [5,13–15], primarily throughControl AFN PEITC AFN+
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ces cytotoxicity. Prx 3 oxidation was measured in HL-60 cells following exposure to
ce of 0.5 lM AFN. (C) and (D) Cell viability was measured after 24 h exposure under
independent experiments.  Indicates a signiﬁcant difference (p < 0.05) between
ultiple comparisons (Systat).
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pathways. There is, however, evidence for a direct effect of isothio-
cyanates on mitochondrial function [16–18]. The exact mecha-
nisms are not clear, with one group linking a small inhibitory
effect on complex III to apoptosis [18], and the other proposing
the effect is independent of the direct targeting of respiratory com-
plexes [16]. Isothiocyanate-afﬁnity probes may prove valuable in
elucidating direct targets within mitochondria [19]. AFN has been
shown to increase hydrogen peroxide production by isolated mito-
chondria, but not in submitochondrial particles with a functional
respiratory chain, therefore it was concluded to primarily act
through impairment of thioredoxin-dependent antioxidant de-
fense [20].
Prx 3 appears to be a valuable marker of mitochondrial redox
homeostasis. It is present endogenously at high concentrations,
thereby eliminating the need for chemical targeting or expression,
and it is extremely reactive [21,22]. It is difﬁcult to determine how
observations obtained with global redox-sensitive probes such as
dichloroﬂuorescein relate to mitochondria [18,23], but the locali-
zation of Prx 3 ensures speciﬁcity. The disadvantage is that the oxi-
dized Prx 3 is continually recycled by the thioredoxin system.
However, the fortuitous observation reported here, that inhibition
of TrxR by AFN alone does not immediately trigger Prx 3 oxidation,
means that low dose AFN can be used to improve the sensitivity of
Prx 3 oxidation as a biomarker.
There is also growing interest in the development of anti-cancer
agents that act on mitochondria [24]. PEITC has been shown to
effectively, and in some cases selectively, sensitize or kill drug-
resistant and oncogenically-transformed cells [23,25–30]. AFN
and related gold complexes are also being explored as anti-cancer
agents [31–33]. From the synergistic effects of AFN observed on
both Prx 3 oxidation and cytotoxicity, we speculate that TrxR
inhibitors may function effectively in combination with other
mitochondrial disrupting agents by overcoming the protection
afforded by Prx 3.
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